Congress Webcasts Home
About Congress Webcasts
Congress Sessions
Obtaining CNE Credits
Faculty Disclosures
Disclaimer
Release & Expiration Dates
ONS

ONS 32nd Annual Congress Sessions

Please note that the session downloading time will vary depending on the session length and your system connection speed.

Click on a session titles below to participate in a webcast. Review system requirements documentation for more information.

Adherence Issues in the Aging Client

A person’s adherence to their plan of care is potentially compromised by many factors, including neurosensory and psychosocial issues. Non-adherence can lead to altered doses, altered schedules, altered pharmacokinetics, and other potentially harmful patient outcomes. Faculty discuss issues that affect adherence and provide clinical examples of compromised adherence.  You will learn from discussions about patient scenarios and you’ll walk away with strategies to implement into your practice to enhance adherence.

Objectives: At the end of this presentation, the participant will be able to:

  1. Identify common elder-specific variables and the physiologic sequelae of nonadherence.
  2. Describe clinical examples of compromised adherence.
  3. Distinguish intervention options to improve adherence in clinical practice.

CNE Credit: 1.6 hours

Supported by an educational grant from AstraZeneca LP and Abraxis Bioscience, Inc.

Advances in the Prevention of Cervical Cancer

Cervical cancer is the 2nd most common cancer in women and a leading cause of morbidity and mortality worldwide.  Participants will learn about current strategies in managing pre-invasive and invasive cervical cancer, screening and early detection strategies, and new prevention strategies including HPV vaccines. Discussion provides an awareness of cervical cancer from a global perspective.

Objectives: At the end of this presentation, the participant will be able to:

  1. Define the incidence and mortality rates of cervical cancer, stages of disease, and screening guidelines.
  2. Explain the development of the HPV vaccine, indications for use, and implications for oncology nurses.
  3. Describe the international perspective and worldwide impact of the disease.

CNE Credit: 1.4 hours

Supported by an educational grant from Merck & Co., Inc.

Current Trends in Neutropenic Fevers and Sepsis

Neutropenic patients are susceptible to a wide range of complications and rare infections that can lead to sepsis.  During this presentation faculty discuss the pathogenesis, predisposing factors, and evaluation and management of neutropenic fevers.  The use of diagnostic testing, identification of microbes through cultures and subsequent species identification, and the selection of treatment and prophylactic antibiotics are addressed.

Objectives: At the end of this presentation, the participant will be able to:

  1. Describe the identification, management, and treatment of neutropenic patients with sepsis.
  2. Discuss the use of diagnostic tests in neutropenic patients.
  3. Review guidelines for the treatment of febrile neutropenia.

CNE Credit: 1.5 hours

Developing a Clinical Program for Survivorship

This session provides an overview of survivorship care models in both the adult and pediatric settings and describe the essential elements of survivorship care. Speakers discuss examples from their clinical experience to describe the implementation of a comprehensive survivorship program and the provision of care for cancer survivors.

Objectives: At the end of this presentation, the participant will be able to:

  1. Describe the needs of cancer survivors and the national recommendations for addressing those needs.
  2. Identify models of care and essential elements of programs for cancer survivors that address their comprehensive needs.
  3. Identify methods for development, implementation, and evaluation of programs for cancer survivors.

CNE Credit: 1.6 hours

Supported by an educational grant from the Lance Armstrong Foundation.

Developing and Implementing a Successful Nurse Navigator Program in Your Community

Navigating the complex maze of cancer care is a challenge for patients and their caregivers.  A relatively new role for oncology nurses is that of “nurse navigator.” Nurse navigators, known as case managers or care coordinators, are experienced oncology nurses who provide guidance to patients to help them understand their diagnosis, treatment options, and to guide them through the various community and supportive resources available to them. Session participants will walk away with tips for developing and implementing a successful navigator program as well as ways to enhance their current program by providing an overview of outcome measures that can be utilized to document effects of nursing interventions.

Objectives: At the end of this presentation, the participant will be able to:

  1. Define the various roles of the nurse navigator in providing care to patients and families with breast health concerns and breast cancer.
  2. Identify how to successfully develop and implement the role of the nurse navigator in his or her practice setting.
  3. Describe how to evaluate the nurse navigator role.

CNE Credit: 1.9 hours

Sponsored by the Breast Care Special Interest Group

DIC: A Case Study in APL

DIC is often a forgotten emergency in the oncology patient. This session is a comprehensive review of the coagulation cascade, physiology of DIC and Acute Leukemia. It evaluates the subset of patients at highest risk for DIC and provide illustrations of the clinical presentation of Acute Leukemia including pathophysiology, current treatment modalities and nursing strategies for management.

Objectives: At the end of this presentation, the participant will be able to:

  1. Evaluate a subset of patients with cancer at highest risk for developing DIC and interventions to manage the emergency.
  2. Explain the inappropriate accelerated and systemic activation of the clotting cascade during DIC that may result in thrombosis and hemorrhage.
  3. Explain diagnostic criteria for acute promyelocytic leukemia, treatment regimens, and potential life-threatening complications in this myeloid hematologic malignancy.

CNE Credit: 1.1 hours

Supported by an educational grant from Cephalon, Inc.

Individualizing Therapeutic Decision-Making in Early-Stage Breast Cancer

This program explores individualizing decision-making about early-stage breast cancer adjuvant therapy, comparing choices made using traditional treatment guidelines, Adjuvant!Online, MammaPrint, and Oncotype DX™. The methods are summarized and compared in their clinical utility at providing individually tailored therapeutic decisions based on relevant patient characteristics. Case discussions explore the various methods, prognostic accuracy, and therapeutic outcomes in a patient with early-stage breast cancer who is estrogen-receptor positive and node-negative.

Objectives: At the end of this presentation, the participant will be able to:

  1. Describe therapeutic decision-making options applicable to patients with early-stage breast cancer who are ER-positive and node negative.
  2. Compare and contrast therapeutic decision-making options, identifying their strengths and limitations in individualizing therapeutic decisions.
  3. Describe the patient populations most suited to the therapeutic decision-making options.
  4. Educate patients about the therapeutic options.
  5. List the ways in which genomic signatures have relevance to patients with breast cancer.
CNE credits: 2.0 with approximately 30 minutes of pharmacology content

Supported by an educational grant from Genomic Health, Inc.

Managing Pain in Cognitively Impaired Patients

Speakers engaged participants in discussions about the under-treatment of pain, assessment techniques for cognitively impaired patients, and tools to evaluate cognitive impairment. Case studies and interactive discussion enhances your confidence to apply this information to your practice.

Objectives: At the end of this presentation, the participant will be able to:

  1. Distinguish a patient’s ability to reliably rate his or her pain using a standard rating tool.
  2. Decide on the most appropriate rating tool to use related to a patient’s cognitive level.
  3. Generate an appropriate assessment plan to communicate to staff appropriate rating methods for cognitively impaired patients.

CNE Credit: 1.6 hours

Supported by an educational grant from Kyphon Inc.

New Management Strategies for CINV

Clinical experts will discuss new strategies for managing CINV, including recent data and evidence-based guidelines.  Interactive vignettes and case studies will set the stage for a faculty led discussion of important issues such as quality of life, evaluating risk, uncontrolled CINV, and access to care.  Worksheets and keypad technology are used to help participants evaluate cases and make decisions to optimize patient outcomes.

Objectives: At the end of this presentation, the participant will be able to:

  1. Identify four risk factors for CINV.
  2. Summarize clinical guidelines related to the management of CINV for low, moderate and high-risk individuals undergoing cancer treatment.
  3. Discuss the gaps in knowledge and on-going research supporting effective management of CINV for patients undergoing cancer treatment.
  4. Apply evidence-based interventions designed to prevent and manage CINV in a case scenario.

Supported by an unrestricted educational grant from Merck, Inc.

Signal Transduction Pathways: Signposts to Improved Therapy for Advanced Renal Cell Carcinoma

This session provides an evidence-based discussion of advanced renal cell carcinoma (RCC), including treatment and symptom management strategies. Case discussion will give participants an opportunity to provide suggestions for assessment and interventions and to demonstrate their understanding of the implications.

Objectives: At the end of this presentation, the participant will be able to:

  1. Differentiate between the mechanisms of action for cytokine therapy and agents that disrupt the VHL and mTor pathways when treating RCC.
  2. Summarize the challenges treating and establishing improved survival rates related to RCC.
  3. Summarize administration considerations for VHL and mTor pathway inhibitors.
  4. List strategies to manage adverse events related to targeted therapies in treating RCC.

CNE Credit: 1.8 hours

Supported by an educational grant from Wyeth Pharmaceuticals

Unraveling the Mysteries of MDS – Linking Science to Practice through Case Studies

Myelodysplastic syndrome (MDS) is a common bone marrow disorder. The clinical hallmark of MDS is ineffective hematopoiesis resulting in “low” peripheral blood counts which may affect all three major cell lines. Over the last several years, the Food and Drug administration has approved three treatments for MDS. This lecture will focus on the clinical and laboratory features of MDS as well as the classification, risk stratification, and prognosis of MDS.  The current FDA-approved treatments will be discussed.  Case studies will be utilized to help participants determine appropriate treatment for selected patients.

Objectives: At the end of this presentation, the participant will be able to:

  1. Summarize MDS pathology as it relates to common symptoms presented in each case study.
  2. Compare prognostic scores and median survival for each group.
  3. Discuss MDS treatment options and management strategies related to each case study.
  4. Understand and explain key nursing considerations for treating patients with MDS.

CNE Credit: 1.5 hours

Supported by an educational grant from Pharmion, Inc.

What’s Blasting Off in CML?

Chronic myelogenous leukemia (CML) is a complex disease that occurs in about 1 in 100,000 people. This webcast will include an overview of the genetic disease development and its phases. Through the presentation of case studies, the participant will gain an improved comprehension of the progression of the disease, current and possible future treatments, and how to identify patients at increased risk for relapse.

Objectives: At the end of this presentation, the participant will be able to:

  1. Summarize CML pathology as it relates to common symptoms.
  2. Discuss CML treatment options and management strategies.
  3. Review important clinical data supporting evidence-based practice in the management of CML.

CNE Credit: 1.6 hours

Supported by an educational grant from Novartis Oncology.